{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"594","value":"1950"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"92"}],"units":"Participants"}],"description":"AUC0-t was defined as the area under the plasma concentration-time curve from time = 0 to the last measurable concentration at time = t.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received retifanlimab 500 milligrams (mg) intravenously every 4 weeks (Q4W).","id":"OG000","title":"Retifanlimab 500 mg"}],"paramType":"MEAN","populationDescription":"PK Evaluable Population","reportingStatus":"POSTED","timeFrame":"pre-infusion on Day 1 of Cycles 1, 2, 4, 6, and 7; 10 minutes and 4 hours post-infusion on Day 1 of Cycles 1 and 6","title":"AUC0-t of Retifanlimab","type":"SECONDARY","unitOfMeasure":"day*mg/L"}